Tina Bhutani

Tina Bhutani

Auto-generated profile, based on publicly available information

Tina Bhutani

Department of Dermatology, University of California San Francisco, San Francisco, California, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2017 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
RSRasnik K. Singh
Rasnik K. Singh
HCHsin-Wen Chang
Hsin-Wen Chang
DYDi Yan
Di Yan
KLKristina M. Lee
Kristina M. Lee
DUDerya Ucmak
Derya Ucmak
WLWilson Liao
Wilson Liao
Recent studies have suggested that the intestinal microbiome plays an important role in modulating risk of several chronic diseases, including inflammatory bowel disease, obesity, type 2 diabetes, cardiovascular disease, and cancer. At the same time, it is now understood that diet plays a significant role in shaping the microbiome, with experiments showing that dietary alterations can induce large, temporary microbial shifts within 24 h. Given this association, there may be significant therapeutic utility in altering microbial composition through diet. This review systematically evaluates current data regarding the effects of several common dietary components on intestinal microbiota. We show that consumption of particular types of food produces predictable shifts in existing host bacterial genera. Furthermore, the identity of these bacteria affects host immune and metabolic parameters, with broad implications for human health. Familiarity with these associations will be of tremendous use to the practitioner as well as the patient.

1 December 2019 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
BMBridget Myers
Bridget Myers
NBNicholas Brownstone
Nicholas Brownstone
VRVidhatha Reddy
Vidhatha Reddy
SCStephanie Chan
Stephanie Chan
QTQuinn Thibodeaux
Quinn Thibodeaux
WLWilson Liao
Wilson Liao

16 October 2019 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
KLKaren Ly
Karen Ly
MSMary P. Smith
Mary P. Smith
QTQuinn Thibodeaux
Quinn Thibodeaux
VRVidhatha Reddy
Vidhatha Reddy
WLWilson Liao
Wilson Liao
TBTina Bhutani
Tina Bhutani
Introduction: Psoriasis is a chronic, immune-mediated disease with significant associated comorbidities. Its pathogenesis is likely multifactorial, however, the interleukin-23/T helper 17 pathway has been identified as a critical axis in its pathogenesis. Interleukin-17A is the primary effector of this pathway and overexpression of IL-17A results in epidermal hyperplasia and an overly robust inflammatory response, resulting in the skin plaques and systemic inflammation seen in psoriasis. Targeted anti IL-17 therapies have demonstrated efficacy in the treatment of moderate-to-severe plaque psoriasis. Areas covered: A PubMed search was conducted for relevant literature. Secukinumab, ixekizumab, and brodalumab are anti IL-17 inhibitors currently approved for the treatment of moderate-to-severe plaque psoriasis. The efficacy and safety data from key phase III clinical trials are reviewed here. Expert opinion: By targeting a key mediator of the interleukin-23/T helper 17 pathway, IL-17 antagonists are an effective treatment for plaque psoriasis. It has demonstrated efficacy and a favorable safety profile in key phase III clinical trials. In addition to efficacy, IL-17 antagonists have also shown long-term maintenance of treatment response and a quick onset of action. The efficacy of IL-17 inhibitors in the treatment of moderate-to-severe psoriasis underscores the importance of the IL-23/Th17 pathway in the pathogenesis of psoriasis.

17 November 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
KEKareem G. Elhage
Kareem G. Elhage
AKAllison Kranyak
Allison Kranyak
JJJoy Qiu Jin
Joy Qiu Jin
KHKathryn Haran
Kathryn Haran
RSRiley K. Spencer
Riley K. Spencer
WLWilson Liao
Wilson Liao
Prior studies have found associations between atopic dermatitis (AD) and comorbidities, including depression, obesity, asthma, and allergic rhinitis. Although observational studies often cannot establish robust causality between potential risk factors and AD, Mendelian randomization minimizes confounding when exploring causality by relying on random allelic assortment at birth. In this study, we systematically reviewed 30 Mendelian randomization studies in AD. Body mass index, gut microbial flora, the IL-18 signaling pathway, and gastroesophageal reflux disease were among the causal factors for AD, whereas AD was causal for several medical conditions, including heart failure, rheumatoid arthritis, and conjunctivitis. These insights may improve preventive counseling in AD.

22 February 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
JJJoy Qiu Jin
Joy Qiu Jin
KEKareem G. Elhage
Kareem G. Elhage
RSRiley K. Spencer
Riley K. Spencer
MDMitchell S. Davis
Mitchell S. Davis
MHMarwa Hakimi
Marwa Hakimi
WLWilson Liao
Wilson Liao
Psoriasis (PSO) and psoriatic arthritis (PSA) are inflammatory diseases with complex genetic and environmental contributions. Although studies have identified environmental and clinical associations with PSO/PSA, causality is difficult to establish. Mendelian randomization (MR) employs the random assortment of genetic alleles at birth to evaluate the causal impact of exposures. We systematically reviewed 27 MR studies in PSO/PSA examining health behaviors, comorbidities, and biomarkers. Exposures, including smoking, obesity, cardiovascular disease, and Crohn's disease, were causal for PSO and PSA, whereas PSO was causally associated with several comorbidities. These findings provide insights that can guide preventive counseling and precision medicine.

1 November 2024 in Psoriasis: Targets and Therapy
Verified
Journal Article
Open access
PDF file
KHKathryn Haran
Kathryn Haran
CJChandler Johnson
Chandler Johnson
PSPayton Smith
Payton Smith
ZVZoë Venable
Zoë Venable
AKAllison Kranyak
Allison Kranyak
WLWilson Liao
Wilson Liao
Psoriasis is an immune-mediated skin disease known to be associated with a higher risk of cardiometabolic comorbidities such as hypertension, myocardial infarction, and stroke. GLP-1 receptor agonists (GLP-1RAs) are medications approved to treat type 2 diabetes mellitus and obesity and have been reported to improve psoriasis. As more psoriasis patients start GLP-1RAs for approved indications, it is of interest to understand the impact of GLP-1RAs on both psoriasis and associated cardiovascular risk. In this review, we examine the effect of GLP-1RAs on psoriasis and cardiovascular comorbidities—defined as hypertension, stroke, and myocardial infarction. The majority of case reports and prospective cohort studies found GLP-1RAs improved psoriasis, while two randomized controlled trials showed conflicting results. For cardiovascular disease, most studies found GLP-1RAs reduced systolic blood pressure, total stroke, and myocardial mortality. These results suggest that GLP-1RAs may be a particularly promising treatment for psoriasis patients with diabetes or obesity comorbidities, offering both cardioprotective benefits and potential improvement in psoriatic symptoms.